WuXi AppTec acquires UK gene therapy company Oxgene
WuXi AppTec has completed its acquisition of Oxgene, a UK contract research and development organization that designs and develops scalable gene therapy technologies.
Oxgene – which will retain its name – will become a fully-owned subsidiary of WuXi Advanced Therapies (WuXi ATU): which is Shanghai-headquartered Wuxi AppTech’s cell and gene therapy Contract Testing, Development and Manufacturing Organization (CTDMO) business unit.
It will be the unit’s first facility in Europe.
Scaling up tech
Oxford biotech Oxgene was founded in 2011. It offers discovery and biomanufacturing solutions to the cell and gene therapy industries through novel technologies and contract research solutions; as well as manufacturing systems. Its novel TESSA technology for adeno-associated viral (AAV) manufacturing and XLenti stable solutions for lentiviral manufacturing are designed to simplify cell and gene therapy manufacturing while reducing costs.